New microfluidic devices or the best drugs to help screen out tumors January 09, 2017 Source: Bio Valley Recently, a research report published in the International Journal of Scientific Reports , researchers from the University of Huddersfield developed a new type of laboratory equipment that could accelerate new resistance. The application of cancer therapy. Researcher Roger Phillips said the device is a small, versatile and easy-to-use microfluidic system that includes a series of trough structures that help scientists monitor the response of hypoxic cells to drugs, hypoxic cells. It will show signs of oxygen deficiency and resistance to therapy. Professor Phillips is an expert in assessing the effects of new anticancer drugs, and he is also very interested in using the microenvironment around the tumor as a target for new drug development, he explains, this new device made of glass and plastic can Help scientists visualize the microenvironment and monitor the cell's response to the test drug in real time. In addition, when the cells being tested grow in the laboratory, they turn into a spheroid, which is distinct from flat-shaped "2D" cells, which can be visualized by scientists in the "3D" cells. The operation and monitoring of the response of the cells to the drug. The researchers said that we can see the drug entering the cell, and can also observe the occurrence of cell hypoxia, and later the system can be used in the study of a series of other diseases. At present, scientists have made great progress in the study of the biological mechanism of cancer cells, but the clinical adaptation of new drugs is still very limited. One of the strategies is to develop new drugs in the in vitro preclinical model to make it better predictable. The success rate of preclinical and clinical testing. Finally, the researchers say that the current microfluidic device can help solve the urgent need for scientists to mimic the in vitro model of the tumor microenvironment, and of course it can help evaluate the early treatment of drugs and accelerate the entry into effective clinical treatment. Go in the application.
Palatin Technologies Inc. (NYSE: PT-141) announced today that it has shown positive results in a Phase I clinical trial of pT-141 for the treatment of sexual dysfunction in normal premenopausal women.
The trial included 32 healthy female volunteers and evaluated their response to pT-141 and placebo in response to visual stimuli. Pt-141 was found to be safe and resulted in a significantly greater improvement in vaginal blood flow than placebo users (P< 0.05).
role
Such antibiotics first affect the outer membrane of sensitive bacteria. Drug ring part of polypeptide amino and lipopolysaccharide in the outer membrane 2 valence cations combining site to produce electrostatic interaction, destroy the integrity of the outer membrane damage, fatty acid part of drugs to penetrate the outer membrane, thus increase the permeability of cell size, lead to intracytoplasmic phosphate, nucleosides and other small molecules to escape, straight die cause cell dysfunction. Gram-positive bacteria do not respond to such antibiotics because they have a thick cell wall that prevents drugs from entering the bacteria.
Pt141 Powder,Bodybuilding Ipamorelin,Sermorelin Powder,Weight Loss Peptide Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptide-nootropics.com
New microfluidic devices or the best drugs to help screen out tumors